These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3743595)

  • 1. Flare reaction during the initial treatment period with medroxyprogesterone acetate in patients with hormone-resistant prostatic cancer.
    Fosså SD; Urnes T
    Eur Urol; 1986; 12(4):257-9. PubMed ID: 3743595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients.
    Flamm J; Spona J
    Int Urol Nephrol; 1988; 20(2):131-7. PubMed ID: 2968326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma].
    Sasagawa I; Satomi S; Katayama T
    Gan No Rinsho; 1989 May; 35(6):767-71. PubMed ID: 2470932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose medroxyprogesterone in the treatment of advanced therapy-resistant prostatic carcinoma.
    Johansson JE; Lingårdh G
    Eur Urol; 1985; 11(1):9-10. PubMed ID: 3157573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
    Fosså SD; Jahnsen JU; Karlsen S; Ogreid P; Haveland H; Trovåg A
    Eur Urol; 1985; 11(1):11-6. PubMed ID: 3157571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study.
    Johansson JE; Andersson SO; Holmberg L
    Br J Urol; 1991 Jul; 68(1):67-73. PubMed ID: 1831397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
    Flamm J; Spona J
    Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.
    Sasagawa I; Satomi S
    Br J Urol; 1990 Mar; 65(3):278-81. PubMed ID: 1692498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.
    Kontturi M; Sotarauta M; Tammela T; Lukkarinen O; Romppainen ML; Gröhn P
    Eur Urol; 1988; 15(1-2):43-7. PubMed ID: 2975221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
    Bezwoda WR
    Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
    Labrie C; Cusan L; Plante M; Lapointe S; Labrie F
    J Steroid Biochem; 1987 Oct; 28(4):379-84. PubMed ID: 2444770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current aspects of hormonal therapy in prostate cancer].
    Altwein JE
    Helv Chir Acta; 1981 Aug; 48(3-4):391-5. PubMed ID: 7287476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
    Anderström C
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S97-100. PubMed ID: 7994797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
    Landström M; Tomić R; Damber JE
    Eur Urol; 1987; 13(3):203-6. PubMed ID: 2956111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer.
    Ruff P; Derman DP; Weaving A; Bezwoda WR
    Oncology; 1989; 46(5):288-92. PubMed ID: 2528705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.